Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in

Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create
  Integrated Approaches to Healthcare Innovation in Newly Published Article

Scientists and business leaders call for models of care that include
therapeutics, devices, tools and services

PR Newswire

TITUSVILLE, N.J., Feb. 5, 2013

TITUSVILLE, N.J., Feb. 5, 2013 /PRNewswire/ --Janssen Research & Development,
LLC, ("Janssen") announced today the publication of a newarticle that
addresses integrated approaches to healthcare solutions. The authors challenge
the healthcare industry to expand its thinking beyond product-focused, "magic
bullet" drug development and discuss the need for an integrated approach to
patient care, including use of devices, tools and services to help a patient's
progress. The commentary, "Beyond magic bullets: true innovation in health
care," was published in the February 2013 issue of Nature Reviews Drug
Discovery and is available at:

"We are in the middle of a revolution for molecular medicine. Advances in the
field are constantly yielding new information about the body and its diseases.
The need to differentiate from existing therapies and the mandate for
innovation are clear," said Husseini K. Manji, M.D., Global Therapeutic Area
Head for Neuroscience, Janssen Research & Development, LLC, and senior author
of the article. "Scientists and business leaders are looking for and
implementing new strategies to bring forth innovative therapeutic approaches
that are meaningful and measurable to patients, caregivers and payers."

The authors discuss solutions for central nervous system (CNS) disorders – a
group of diseases and illnesses identified as one of the biggest challenges to
our healthcare and economic environment. The predicted cost of these disorders
to society worldwide is higher than that of cancer, diabetes and chronic
respiratory diseases combined,[1] and many serious mental illnesses, for
example, can affect a patient's ability to take medicines on a regular basis
and become engaged in a treatment plan. The authors suggest that a "beyond the
pill" integrated care model – including ongoing remote analysis of
physiological and activity-based parameters using on-body sensors, or even
mobile technology such as smart phones – has the potential toadvance disease
management and treatment efficacy. Such technologies and advances must be
developed and introduced in collaboration with patient advocacy groups and
with appropriate education for and consent of patients and caregivers.

"Treatment plans that leverage combined benefits of a pharmaceutical product
with devices and programs that support medication adherence and access to
treatment and services may be the shift needed to keep pace with the disease
management challenges, especially in neurodegenerative disease and mental
illness," said Dr. Manji.

Research supports the authors' views. In the treatment of schizophrenia, for
example,integrated care including medication and a holistic care program to
look after a patient's medication adherence and provide other therapeutic
elements can lead to a decrease in relapse-related hospitalization. In
Germany, significant reductions in relapse-related hospitalization rates have
been achieved for patients with schizophrenia and bipolar disorder who were
enrolled in integrated care models. Such programs can contribute to improved
quality of care and better medication adherence. 

"Integrated models have the potential to radically change patient care as we
know it, while being sensitive to the time demands of caregivers," said
co-author Michael Yang, President, Janssen Pharmaceuticals, Inc. "As we
advance at the molecular and disease biology level, we also must evolve
business models so that our healthcare ecosystem can improve outcomes for
patients who have some of the most devastating diseases."

About Janssen's Healthy Minds Program
Janssen's interests in integrated care for brain diseases have a direct
connection to the Janssen Healthy Minds program, launched in 2011 to encourage
collaboration among biotechnology, pharmaceutical and public-sector
organizations to accelerate the discovery of new therapeutic solutions for
neurologic and brain diseases. Healthy Minds builds on Janssen's longstanding
legacy of achievement in advancing neuroscience research. The company's work
in this area dates back to the 1950s, when Dr. Paul Janssen's discovery and
development work led to one of the first breakthrough treatments for
schizophrenia. Janssen is named for "Dr. Paul," who is known as one of the
20th century's most gifted and passionate physicians and pharmaceutical

Over the last half century, Janssen has discovered, developed and launched
many innovative treatments for brain and CNS conditions and remains firmly
committed to neuroscience. Janssen commits more than $12 million annually to
public and professional education about mental illness and brain disorders,
sponsorships and philanthropy in the field of neuroscience and mental health.

About Janssen Research & Development, LLC
At Janssen Research & Development, LLC, we are united and energized by one
mission – to discover and develop innovative medicines that ease patients'
suffering, and solve the most important unmet medical needs of our time. As
one of the Janssen Pharmaceutical Companies of Johnson & Johnson, our strategy
is to identify the biggest unmet medical needs and match them with the best
science, internal or external, to find solutions for patients worldwide. We
leverage our world-class discovery and development expertise, and operational
excellence, to bring innovative, effective treatments in oncology, immunology,
neuroscience, infectious diseases and vaccines, and cardiovascular and
metabolic diseases. For more information on Janssen R&D, visit

About Janssen Pharmaceuticals, Inc.
As a member of the Janssen Pharmaceutical Companies of Johnson & Johnson,
Janssen Pharmaceuticals, Inc., is dedicated to addressing and solving some of
the most important unmet medical needs of our time.Driven by our commitment
to patients, we work together to bring innovative ideas, products, services
and solutions to individuals with serious conditions, and to physicians
throughout the world. For more information on Janssen Pharmaceuticals, Inc. or
its products, visit us atwww.janssenpharmaceuticalsinc.com or follow us on
Twitter atwww.twitter.com/JanssenUS.

[1] World Economic Forum. The Global Economic Burden of Non-communicable
Diseases (Harvard School of Public Health, 2011).

Media Contact:
Greg Panico
Janssen Global Services, LLC
609-730-3061 (office)

SOURCE Janssen Research & Development, LLC

Website: http://www.janssenrnd.com
Press spacebar to pause and continue. Press esc to stop.